TABLE 1.

Adherence to the criteria of MAT_STEMI (n = 232).

No	Criteria a	Applicability	% Adjusted Adherence (95%CI)
Antithrombotic therapy
1	Patient with no contraindication to aspirin is prescribed a daily dose of aspirin 81–325 mg, indefinitely	230	90.4 (85.7–93.8)
2	Patient who is not prescribed aspirin due to hypersensitivity is prescribed clopidogrel 75 mg daily	23	100 (82.2–99.6)
3	Patient with stent post-primary PCI is prescribed clopidogrel 75 mg or ticagrelor 90 mg BID daily for at least 12 months, in addition to aspirin 81 mg as a dual therapy	135	77.0 (68.9–83.7)
4	Patient post-fibrinolysis without subsequent PCI is prescribed clopidogrel 75 mg daily in addition to aspirin for at least 14 days and up to 1 year in absence of bleeding	8	37.5 (10.2–74.1)
5	Patient post-fibrinolysis with subsequent PCI is prescribed clopidogrel 75 mg daily in addition to aspirin for 12 months	64	90.6 (80.1–96.1)
6	Patient on dual antiplatelet therapy and at higher than average risk of gastrointestinal bleeding is prescribed a proton pump inhibitor	23	82.6 (60.5–94.3)
Beta-blockers
7	Patient with no contraindications to beta-blockers is prescribed a beta-blocker	231	93.9 (89.82–96.5)
8	Patient with no contraindications to beta-blockers and prescribed a beta-blocker is prescribed metoprolol succinate SR, bisoprolol, or carvedilol for up to 3 years	160	92.5 (87.0–95.9)
9	Patient with no contraindications to beta-blockers with an LVEF ≤ 40% and prescribed a beta-blocker is prescribed either a metoprolol succinate SR, bisoprolol, or carvedilol indefinitely	61	93.4 (83.3–97.9)
Lipid-lowering therapies
10	Patient regardless of the lipid level is prescribed a high intensity statin either atorvastatin 40–80 mg or rosuvastatin 20–40 mg	232	45.7 (39.2–52.3)
11	Patient prescribed a high intensity statin is prescribed atorvastatin 80 mg	104	22.1 (14.8–31.5)
12	Patient maintained on statins with a baseline LDL level 1.8–3.5 mmol/L has achieved a target LDL cholesterol <1.8 mmol/L or at least 50% reduction in LDL cholesterol	231	48.9 (42.3–55.5
13	Patient with an LDL ≥ 1.8 mmol/L and despite a maximally tolerated statin should be on further therapy (ezetimibe)	79	10.1 (4.8–19.5)
Inhibitors of renin–angiotensin–aldosterone system
14	Patient with no contraindication to ACE inhibitors is prescribed an ACE inhibitor	191	91.6 (86.5–95.0)
15	Patient not prescribed ACE inhibitor due to intolerance is prescribed ARB	33	100 (87.0–99.7)
16	Patient already receiving an ACEI and beta-blocker and have LVEF ≤ 40%, and either heart failure or diabetes (without significant renal dysfunction, or hyperkalemia) is prescribed an aldosterone antagonist	55	54.6 (40.7–67.8)

^aCriteria were developed and validated from the ESC guidelines (Roffi et al., 2016; Ibanez et al., 2018) and the ACC/AHA guidelines (Amsterdam et al., 2014; O'Gara et al., 2013).